Compare · ABT vs ROIV
ABT vs ROIV
Side-by-side comparison of Abbott Laboratories (ABT) and Roivant Sciences Ltd. (ROIV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ROIV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $155.49B, about 6.2x ROIV ($25.10B).
- Over the past year, ABT is down 32.3% and ROIV is up 202.5% - ROIV leads by 234.7 points.
- ROIV has been more active in the news (14 items in the past 4 weeks vs 10 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 18 for ROIV).
- Company
- Abbott Laboratories
- Roivant Sciences Ltd.
- Price
- $89.26+0.35%
- $34.88-0.14%
- Market cap
- $155.49B
- $25.10B
- 1M return
- +1.33%
- +16.06%
- 1Y return
- -32.25%
- +202.47%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 10
- 14
- Recent ratings
- 25
- 18
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Latest ABT
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
- Abbott hosts conference call for second-quarter earnings
- ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing
Latest ROIV
- CEO Gline Matthew covered exercise/tax liability with 76,171 shares, decreasing direct ownership by 0.46% to 16,659,945 units (SEC Form 4) (for withholding tax)
- Director Fitzgerald Meghan exercised 10,000 shares at a strike of $8.80 and sold $349,000 worth of shares (10,000 units at $34.90) (SEC Form 4)
- President and Vant Chair Torti Frank covered exercise/tax liability with 40,310 shares, decreasing direct ownership by 0.30% to 13,536,202 units (SEC Form 4) to cover withholding tax
- President & CIO Sukhatme Mayukh covered exercise/tax liability with 46,878 shares, decreasing direct ownership by 0.25% to 18,630,739 units (SEC Form 4) to satisfy tax liability
- Director Epperly Melissa B, sold $610,252 worth of shares (17,750 units at $34.38) and exercised 17,750 shares at a strike of $4.46 (SEC Form 4)
- Director Manchester Keith S sold $56,444,076 worth of shares (1,638,163 units at $34.46), decreasing direct ownership by 10% to 1,748,403 units (SEC Form 4)
- Director Gold Daniel Allen sold $49,354,076 worth of shares (1,438,163 units at $34.32) (SEC Form 4)
- Director by Deputization Qvt Financial Lp sold $49,354,076 worth of shares (1,438,163 units at $34.32) (SEC Form 4)
- SEC Form 144 filed by Roivant Sciences Ltd.
- SEC Form 144 filed by Roivant Sciences Ltd.